Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C.
Veldt BJ, van der Vliet HJ, von Blomberg BM, van Vlierberghe H, Gerken G, Nishi N, Hayashi K, Scheper RJ, de Knegt RJ, van den Eertwegh AJ, Janssen HL, van Nieuwkerk CM. Veldt BJ, et al. Among authors: van vlierberghe h, van der vliet hj, van den eertwegh aj, van nieuwkerk cm. J Hepatol. 2007 Sep;47(3):356-65. doi: 10.1016/j.jhep.2007.04.018. Epub 2007 Jun 6. J Hepatol. 2007. PMID: 17599630 Clinical Trial.
Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial.
Van Vlierberghe H, Leroux-Roels G, Adler M, Bourgeois N, Nevens F, Horsmans Y, Brouwer J, Colle I, Delwaide J, Brenard R, Bastens B, Henrion J, de Vries RA, de Galocsy C, Michielsen P, Robaeys G, Bruckers L. Van Vlierberghe H, et al. J Viral Hepat. 2003 Nov;10(6):460-6. doi: 10.1046/j.1365-2893.2003.00466.x. J Viral Hepat. 2003. PMID: 14633181 Clinical Trial.
Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients.
Brouwer JT, Nevens F, Bekkering FC, Bourgeois N, Van Vlierberghe H, Weegink CJ, Lefebvre V, Van Hattum J, Henrion J, Delwaide J, Hansen BE, Schalm SW; Benelux Study Group On Treatment Of Chronic Hepatitis C. Brouwer JT, et al. Among authors: van hattum j, van vlierberghe h. J Hepatol. 2004 Apr;40(4):689-95. doi: 10.1016/j.jhep.2003.12.017. J Hepatol. 2004. PMID: 15030987 Clinical Trial.
Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes.
Robaeys G, Van Vlierberghe H, Matheï C, Van Ranst M, Bruckers L, Buntinx F; BASL Steering Committee; Benelux Study Group. Robaeys G, et al. Among authors: van vlierberghe h, van ranst m. Eur J Gastroenterol Hepatol. 2006 Feb;18(2):159-66. doi: 10.1097/00042737-200602000-00008. Eur J Gastroenterol Hepatol. 2006. PMID: 16394797 Clinical Trial.
Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H, Desombere I, Hansen B, Van Vlierberghe H, Haagmans B, De Knegt RJ, Schalm SW, Leroux-Roels G, Janssen HL; DITTO-HCV Study Group. Orlent H, et al. Among authors: van vlierberghe h. Eur J Gastroenterol Hepatol. 2010 Dec;22(12):1443-8. doi: 10.1097/MEG.0b013e32833ef6e3. Eur J Gastroenterol Hepatol. 2010. PMID: 21389795 Clinical Trial.
343 results